Cargando…

Anticarcinogenic Effects of Odorant Substances Citral, Citrathal R and Cyclovertal on Breast Cancer in vitro

PURPOSE: In 2020, breast cancer still represents the most common type of cancer in women worldwide. Depending on the specific molecular subtype, clinical breast cancer management comprises surgery, radiotherapy, chemotherapy and targeted therapy. Furthermore, there are some therapeutic approaches fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Klauser, Anna-Lena, Hirschfeld, Marc, Ritter, Andrea, Rücker, Gerta, Jäger, Markus, Gundarova, Julia, Weiss, Daniela, Juhasz-Böss, Ingolf, Berner, Kai, Erbes, Thalia, Asberger, Jasmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668161/
https://www.ncbi.nlm.nih.gov/pubmed/34916844
http://dx.doi.org/10.2147/BCTT.S322619
_version_ 1784614512993763328
author Klauser, Anna-Lena
Hirschfeld, Marc
Ritter, Andrea
Rücker, Gerta
Jäger, Markus
Gundarova, Julia
Weiss, Daniela
Juhasz-Böss, Ingolf
Berner, Kai
Erbes, Thalia
Asberger, Jasmin
author_facet Klauser, Anna-Lena
Hirschfeld, Marc
Ritter, Andrea
Rücker, Gerta
Jäger, Markus
Gundarova, Julia
Weiss, Daniela
Juhasz-Böss, Ingolf
Berner, Kai
Erbes, Thalia
Asberger, Jasmin
author_sort Klauser, Anna-Lena
collection PubMed
description PURPOSE: In 2020, breast cancer still represents the most common type of cancer in women worldwide. Depending on the specific molecular subtype, clinical breast cancer management comprises surgery, radiotherapy, chemotherapy and targeted therapy. Furthermore, there are some therapeutic approaches from the field of complementary and alternative medicine. Current research focuses on the elucidation of new therapeutic targets for treatment development. Odorant substances affect apoptosis, proliferation and cell cycle in healthy and cancerous cells. Exact signalling pathways involved are not entirely clear. The present study aims to analyse their therapeutic potential in breast cancer. METHODS: This study focuses on the effect of commonly used odorant substances (citral, citrathal R, cyclovertal, para-cymol, hexylacetat, herbavert, dihydromyrcerol and limonen) on the breast cancer cell lines MDA-MB-231, T47-D and BT474. Methodologically, this study applied cell culturing, MTT assay for detection of IC50 of the odorant substance, RNA purification followed by qRT-PCR, protein isolation and Western Blot, as well as immunocytochemistry. Further, this study investigates the role of transient receptor potential channel V1 (TRPV1), involved in the mechanisms of action for some odorant substances. Therefore, capsazepine, a TRPV1 antagonist, was used. RESULTS: The odorant substances citral, citrathal R and cyclovertal have significant pro-apoptotic (p < 0.001), anti-proliferative (p < 0.001) and cell cycle-arresting effects measurable in RNA expression as well as in protein levels and immunocytochemical staining. The combination of citral and capsazepine no longer showed significant pro-apoptotic, antiproliferative, and cell cycle inhibitory effects compared to the compounds alone. This indicates that TRPV1 is necessary for the signal transduction of citral. CONCLUSION: This present study reveals three odorant substances with effects on cell viability, indicating their potential use in breast cancer therapy.
format Online
Article
Text
id pubmed-8668161
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-86681612021-12-15 Anticarcinogenic Effects of Odorant Substances Citral, Citrathal R and Cyclovertal on Breast Cancer in vitro Klauser, Anna-Lena Hirschfeld, Marc Ritter, Andrea Rücker, Gerta Jäger, Markus Gundarova, Julia Weiss, Daniela Juhasz-Böss, Ingolf Berner, Kai Erbes, Thalia Asberger, Jasmin Breast Cancer (Dove Med Press) Original Research PURPOSE: In 2020, breast cancer still represents the most common type of cancer in women worldwide. Depending on the specific molecular subtype, clinical breast cancer management comprises surgery, radiotherapy, chemotherapy and targeted therapy. Furthermore, there are some therapeutic approaches from the field of complementary and alternative medicine. Current research focuses on the elucidation of new therapeutic targets for treatment development. Odorant substances affect apoptosis, proliferation and cell cycle in healthy and cancerous cells. Exact signalling pathways involved are not entirely clear. The present study aims to analyse their therapeutic potential in breast cancer. METHODS: This study focuses on the effect of commonly used odorant substances (citral, citrathal R, cyclovertal, para-cymol, hexylacetat, herbavert, dihydromyrcerol and limonen) on the breast cancer cell lines MDA-MB-231, T47-D and BT474. Methodologically, this study applied cell culturing, MTT assay for detection of IC50 of the odorant substance, RNA purification followed by qRT-PCR, protein isolation and Western Blot, as well as immunocytochemistry. Further, this study investigates the role of transient receptor potential channel V1 (TRPV1), involved in the mechanisms of action for some odorant substances. Therefore, capsazepine, a TRPV1 antagonist, was used. RESULTS: The odorant substances citral, citrathal R and cyclovertal have significant pro-apoptotic (p < 0.001), anti-proliferative (p < 0.001) and cell cycle-arresting effects measurable in RNA expression as well as in protein levels and immunocytochemical staining. The combination of citral and capsazepine no longer showed significant pro-apoptotic, antiproliferative, and cell cycle inhibitory effects compared to the compounds alone. This indicates that TRPV1 is necessary for the signal transduction of citral. CONCLUSION: This present study reveals three odorant substances with effects on cell viability, indicating their potential use in breast cancer therapy. Dove 2021-12-08 /pmc/articles/PMC8668161/ /pubmed/34916844 http://dx.doi.org/10.2147/BCTT.S322619 Text en © 2021 Klauser et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Klauser, Anna-Lena
Hirschfeld, Marc
Ritter, Andrea
Rücker, Gerta
Jäger, Markus
Gundarova, Julia
Weiss, Daniela
Juhasz-Böss, Ingolf
Berner, Kai
Erbes, Thalia
Asberger, Jasmin
Anticarcinogenic Effects of Odorant Substances Citral, Citrathal R and Cyclovertal on Breast Cancer in vitro
title Anticarcinogenic Effects of Odorant Substances Citral, Citrathal R and Cyclovertal on Breast Cancer in vitro
title_full Anticarcinogenic Effects of Odorant Substances Citral, Citrathal R and Cyclovertal on Breast Cancer in vitro
title_fullStr Anticarcinogenic Effects of Odorant Substances Citral, Citrathal R and Cyclovertal on Breast Cancer in vitro
title_full_unstemmed Anticarcinogenic Effects of Odorant Substances Citral, Citrathal R and Cyclovertal on Breast Cancer in vitro
title_short Anticarcinogenic Effects of Odorant Substances Citral, Citrathal R and Cyclovertal on Breast Cancer in vitro
title_sort anticarcinogenic effects of odorant substances citral, citrathal r and cyclovertal on breast cancer in vitro
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668161/
https://www.ncbi.nlm.nih.gov/pubmed/34916844
http://dx.doi.org/10.2147/BCTT.S322619
work_keys_str_mv AT klauserannalena anticarcinogeniceffectsofodorantsubstancescitralcitrathalrandcyclovertalonbreastcancerinvitro
AT hirschfeldmarc anticarcinogeniceffectsofodorantsubstancescitralcitrathalrandcyclovertalonbreastcancerinvitro
AT ritterandrea anticarcinogeniceffectsofodorantsubstancescitralcitrathalrandcyclovertalonbreastcancerinvitro
AT ruckergerta anticarcinogeniceffectsofodorantsubstancescitralcitrathalrandcyclovertalonbreastcancerinvitro
AT jagermarkus anticarcinogeniceffectsofodorantsubstancescitralcitrathalrandcyclovertalonbreastcancerinvitro
AT gundarovajulia anticarcinogeniceffectsofodorantsubstancescitralcitrathalrandcyclovertalonbreastcancerinvitro
AT weissdaniela anticarcinogeniceffectsofodorantsubstancescitralcitrathalrandcyclovertalonbreastcancerinvitro
AT juhaszbossingolf anticarcinogeniceffectsofodorantsubstancescitralcitrathalrandcyclovertalonbreastcancerinvitro
AT bernerkai anticarcinogeniceffectsofodorantsubstancescitralcitrathalrandcyclovertalonbreastcancerinvitro
AT erbesthalia anticarcinogeniceffectsofodorantsubstancescitralcitrathalrandcyclovertalonbreastcancerinvitro
AT asbergerjasmin anticarcinogeniceffectsofodorantsubstancescitralcitrathalrandcyclovertalonbreastcancerinvitro